Sections

Alphabetical list:

A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9

News: November 29, 2009

Rituximab May Offer Hope To Severe Graves' Eye Disease Patients

November 29, 2009

There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.

This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.

Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.

Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.50.8 to 1.30.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.

Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 243.7 mm before therapy and 23.63.7 mm after therapy; P = 0.17).

"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."

Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.

Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.

"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.

Source

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029


University of Michigan Health System Newsroom



Archive issues: (50)

Archive list: 1 2 3 4 5 6 7 [8] 9 10 11 12 13 14 15 16 17

November 23, 2009 | Genetic Variant Slows AIDS Progression

Scientists report that a genetic variation appears to play a major role in slowing disease progression in HIV-infected patients.  In fact, those with the variation appear to take years longer to develop AIDS and die of complications of the disease.  "We're honing in on factors that vary across individuals that make a person more or less susceptible to HIV, in ...

November 22, 2009 | FDA To Reduce the Misuse of Medications

The FDA wants to reduce the misuse of medications, saying that at least 50,000 hospitalizations a year could be prevented if physicians, pharmacists, patients and parents would be more careful. And the cost of these preventable injuries is estimated at about $4 billion annually by the Institute of ...

November 21, 2009 | Diabetes Drug Byetta Linked to Kidney Problems

The FDA has received 78 reports of kidney problems related to Byetta, a drug by Amylin Pharmaceuticals and Eli-Lilly prescribed to treat type 2 diabetes. With the new findings, the drug's label will be updated to warn doctors and patients about this possible side effect.  Byetta (exenatide) was ...

Archive list: 1 2 3 4 5 6 7 [8] 9 10 11 12 13 14 15 16 17

Related articles:

Chronic prostatitis/chronic pelvic pain syndrome - signs and symptoms

  These patients have no history of genitourinary pain complaints, but leukocytosis is noted, usually during evaluation for other conditions.    

Section: Prostatitis

Risk-taking - media encouragement

  According to Arran Stibbe, men's health problems and behaviors can be linked to the socialized gender role of men in our culture. In exploring magazines, he found that they promote traditional masculinity. The magazine celebrates "male" things such as liking guns, fast cars, and fast ...

Section: Mens health risks

Risk-taking - alcohol consumption behavior

  Research on beer commercials by Strate (Postman, Nystrom, Strate, And Weingartner 1987; Strate 1989, 1990) and by Wenner (1991) show some interesting results. In beer commercials, the ideas of masculinity (especially risk-taking) are presented and encouraged. The commercial focuses on a situation where a man is overcoming an obstacle in a group. The men will either be working hard or playing hard. For instance the commercial will show men who do physical labor such as cowboys, construction workers, or farm hands. The beer is shown as ...

Section: Mens health risks

News

December 20, 2009

Wii, Xbox 360 and Other Video Games Offer Some Benefits

Wii, Xbox 360, PlayStation, and other video games are hot on holiday gift lists, but some parents wonder whether these games offer any benefits or are detrimental to kids. The results of a new study may put some minds at ease, while others may not.  According to the findings reported in the latest issue of Current Directions in Psychological Science, ...

December 18, 2009

Should You Be Shoveling Snow?

Yes, the weather outside is frightful, and soon you will have to think about shoveling snow. But should you be the one doing the work? Who should and should not shovel snow, and how can you do it safely?  Every ...

December 17, 2009

Athletes who take NSAID's to prevent pain may be doing more harm than good

According to Stuart Warden, a researcher who studies musculoskeletal health and sports medicine, athletes who ritualistically take NSAID's to prevent post event and workout soreness and inflammation may be depriving the body of healing, in ...

Blogroll